Wirtek

B&O bag tallene, NORDEN opjusterer, Ascelias skæbnedag hos FDA og Wirtek vinder i Irland: her er morgenens vigtigste.

Vi havde fornøjelse af at gå igennem Voldgiftsretten med Pharma Equity Group, sammen med bestyrelsesformand Christian Vinding, herudover er der netop nu spændene muligheder indenfor den danske IT-servicesektor.

Wirtek eksekverer på strategien med ikke-bindende opkøbsaftale om profitabelt dansk SaaS-selskab. Et opkøb, der kan understøtte skiftet fra timebaserede services mod løsninger med tilbagevendende omsætning og blue-chip kunder i life sciences, forsvar og energi

Dagens aktienyheder 18/05-2026: WindowMaster, RTX, Wirtek og Ascelia Pharma

Following Wirtek's Q1 2026 interim report, we have updated our investment case to reflect the first full quarter of impact from the new strategy launched last year. Our investment case covers the key investment reasons and risks and valuation perspectives.

Today, Wirtek’s CEO Michael Aaen and CFO Mads Greiffenberg presented the company’s Q1 2026 results , and what is driving the increased profitability despite muted topline growth The presentation was followed by a Q&A session.

Wirtek is expected to release its Q1 2026 interim report on May 13, 2026. On the same day at 12:30 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session. In connection with the 2025 annual report, Wirtek launched guidance for 2026 with revenue in the range of DKK 65-70m (growth of 1-9% compared to 2025) and EBITDA of DKK 3-6m (compared to DKK 1.7m in 2025). The guidance signals a return to growth and significantly improved profitability following a transitional year in 2025.

Mød ledelsen i H. Lundbeck, Wirtek, Ascelia Pharma og GrønlandsBANKEN, og stil spørgsmål til dagens investorpræsentationer